Curevac will launch its third phase of clinical trials for its Covid-19 vaccine, the German pharmaceutical laboratory announced on Monday.
The company “has enrolled the first participant in the pivotal Phase 2b/3 study,” it said in a press release.
More than 35,000 participants across Europe and Latin America are expected to take part in the trials, according to Curevac.
Moving on to phases 2b and 3 marks “another important milestone in the development of our vaccine candidate, CVnCoV,” said CureVac CEO, Dr. Franz-Werner Haas, in the press release, adding that the data look promising.
The vaccine’s efficacy “will be assessed by an event-driven analysis based on a certain number of participants who present with laboratory confirmed symptomatic COVID-19 disease during the study,” the company said.
Related News
- Pfizer vaccine: Belgium receives fewer doses than expected in January
- AstraZeneca to test combination with Russian Covid-19 vaccine
- Over half of Brussels doesn't want a Covid-19 vaccine in January
Curevac is one of many companies racing to develop a coronavirus vaccine. On 2 December, Pfizer - BioNTech’s vaccine was approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA), with vaccinations following a week later.
The US Food and Drug Administration (FDA) also approved the Pfizer vaccine on Saturday. Meanwhile, the European Medicines Agency (EMA) has yet to approve a coronavirus vaccine.
Jason Spinks
The Brussels Times
